FDA Green Lights Arkis Biosciences' CerebroFlo EVD Catheter With Endexo Technology

Published: Sep 20, 2017

Arkis Biosciences Achieves FDA Clearance of its CerebroFlo EVD Catheter with Endexo Technology

KNOXVILLE, Tenn., Sept. 19, 2017 /PRNewswire/ -- Arkis BioSciences, a leading innovator in minimally invasive surgical instrumentation, has obtained FDA clearance of its new external ventricular drainage catheter, CerebroFlo

According to Chad Seaver, CEO of Arkis BioSciences, the new catheter will be used for insertion into a ventricular cavity of the brain for external drainage of cerebrospinal fluid in patients with elevated intracranial pressure, intraventricular hemorrhage, or hydrocephalic shunt infections. 

"Arkis' CerebroFlo catheter is the first neuro catheter to incorporate Endexo®, a permanent polymer additive whose properties have been shown to reduce protein adhesion and activation in laboratory in vitro studies," said Seaver. "The catheter's Endexo formulation has properties that may lead to reduced complications such as catheter occlusion and infection."

Seaver says Arkis plans to introduce the device to the U.S. market at the upcoming annual Congress of Neurological Surgeons (booth 747), which will be held in Boston, MA, Oct. 7-11, 2017, and plans for international distribution beginning in 2018. 

"The clearance of CerebroFlo marks an expansion of Arkis' surgical line, extending our reach into neurocritical care," said Seaver. "Arkis' new CerebroFlo catheter is poised to disrupt the neuro catheter market with its Endexo technology."

Seaver explains Endexo is a catheter technology exclusively licensed to Arkis by Interface Biologics, Inc.® for neurological cerebrospinal fluid applications.  Clinical studies of other catheters incorporating Endexo have shown patient benefits including markedly reduced obstructions, fewer infections, and overall lower treatment costs. 

"Arkis' in vitro studies have shown 99% less biomatter accumulation onto CerebroFlo's catheter surfaces, which may reduce fouling," said Seaver. "Further in vitro studies are underway to characterize CerebroFlo's ability to prevent infectious biofilm formations without the use of eluting antibiotic drugs."

"Given the early success we have seen with our new tunneling guidewire line, I'm excited to now introduce this innovative neuro catheter to current and prospective customers," said Ryan Gray, Arkis' Director of Sales.  "Existing ventricular catheters are particularly problematic due to obstructions and Endexo has the potential to make a remarkable difference to patients."

About Arkis BioSciences Inc.

Arkis BioSciences® is a leading innovator and provider of minimally invasive surgical instrumentation and catheters for neuro-, general-, and plastic-surgeries.  The company's tunneling guidewire line of instrumentation and its proprietary Single Pass workflow potentially enable less invasive and less traumatic procedures.  Additionally, Arkis provides advanced materials for neuro catheters, which incorporate Endexo.  Arkis BioSciences is headquartered in Knoxville, Tennessee and began operations in 2013.  For further information, please visit www.arkisbiosciences.com.



View original content with multimedia:http://www.prnewswire.com/news-releases/arkis-biosciences-achieves-fda-clearance-of-its-cerebroflo-evd-catheter-with-endexo-technology-300522094.html

SOURCE Arkis BioSciences

Back to news